About medicinova inc - MNOV
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
MNOV At a Glance
MediciNova, Inc.
4275 Executive Square
La Jolla, California 92037
| Phone | 1-858-373-1500 | Revenue | 409.66K | |
| Industry | Pharmaceuticals: Major | Net Income | -11,997,957.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MNOV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 156.895 |
| Price to Book Ratio | 1.551 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.573 |
| Enterprise Value to Sales | 82.21 |
| Total Debt to Enterprise Value | 0.006 |
MNOV Efficiency
| Revenue/Employee | 68,276.167 |
| Income Per Employee | -1,999,659.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.008 |
MNOV Liquidity
| Current Ratio | 8.161 |
| Quick Ratio | 8.161 |
| Cash Ratio | 8.112 |
MNOV Profitability
| Gross Margin | 2.673 |
| Operating Margin | -3,242.469 |
| Pretax Margin | -2,927.318 |
| Net Margin | -2,928.781 |
| Return on Assets | -23.646 |
| Return on Equity | -25.503 |
| Return on Total Capital | -28.705 |
| Return on Invested Capital | -25.441 |
MNOV Capital Structure
| Total Debt to Total Equity | 0.508 |
| Total Debt to Total Capital | 0.506 |
| Total Debt to Total Assets | 0.464 |
| Long-Term Debt to Equity | 0.041 |
| Long-Term Debt to Total Capital | 0.041 |